Quantcast

Latest Chemokine Stories

2009-04-14 07:30:00

Trial to Evaluate Safety of CCL2-LPM for Inflammatory Kidney Disease SAN FRANCISCO, April 14 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., Inc. announced today that patient dosing has commenced in a Phase Ib clinical trial of the company's lead compound, CCL2-LPM, for the treatment of IgA nephropathy, an inflammatory kidney disease. Osprey Pharmaceuticals U.S.A. is developing novel chemokine-enzyme fusion protein therapeutics, known as Leukocyte Population Modulators (LPMs), for the...

2009-04-08 08:46:14

An inflammatory factor already linked to several diseases, including pulmonary disease, lung cancer, and arthritis, may also be responsible for the insulin resistance that comes with obesity, according to a new study published in the April issue of Cell Metabolism, a Cell Press publication.Researchers have found that the inflammatory chemokine known as CXCL5 rises and falls with obesity and subsequent weight loss in humans. (Chemokines are structurally related signaling proteins that are...

2009-02-03 06:00:00

Therapeutic Approach Provides HIV-Resistant Immune Cells RICHMOND, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the treatment of HIV/AIDS. Based on Sangamo's zinc finger DNA-binding protein nuclease (ZFN) technology, SB-728-T has been shown in an animal model of HIV infection to lead to an increase in CD4+ T-cell...

92365227d48105f53ed411c249b276f51
2009-01-30 09:38:58

Research published in the Journal of Leukocyte Biology identifies eotaxin as a novel drug target If you've ever wondered why some allergic reactions progress quickly and may even become fatal, a new research report published in the February 2009 issue of the Journal of Leukocyte Biology provides an important part of the answer. In the report, scientists from Queen's University of Belfast, University of Oxford and Trinity College Dublin show for the first time that eotaxin, a chemical that...

2009-01-05 14:54:00

San Diego-Based Carolus Therapeutics Focuses on Discovery and Development of Anti-Inflammatory Drugs Based on Collaborators' Findings at RWTH Aachen University in Germany SAN DIEGO, Jan. 5 /PRNewswire/ -- Research published in Nature Medicine shows that the disruption of the interactions between two small signaling proteins called chemokines by a highly potent drug-like peptide inhibits the development of atherosclerosis in mice. San Diego-based Carolus Therapeutics Inc., which has...

5ee4b95a2b75a816a69d4d466caa0a3c1
2008-11-27 10:06:17

Irregular, heavy drinking pattern clogs blood vessels As the holidays arrive, a group of researchers has identified the precise mechanisms by which binge drinking contributes to clogs in arteries that lead to heart attack and stroke, according to a study published today in the journal Atherosclerosis. The works adds to a growing body of evidence that drinking patterns matter as much, if not more, to risk for cardiovascular disease than the total amount consumed. According to the National...

2008-10-28 18:00:28

WASHINGTON and RICHMOND, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today the presentation of data demonstrating that human CD4 T-cells can be made permanently resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)) resulting in an increase in CD4 T-cell counts and a reduction in viral load in an animal model of HIV infection. The presentation, entitled, "Establishment of HIV Resistant CD4 T-cells Using Engineered...

2008-10-16 12:00:25

ChemoCentryx, a clinical-stage biopharmaceutical company, has initiated a Phase I clinical trial of CCX025, the company's fourth investigational new drug and second orally administered compound that inhibits the chemokine receptor known as CCR9. The Phase I double-blind, placebo-controlled trial of CCX025 is being conducted in healthy male and female volunteers to evaluate the safety, tolerability and pharmacokinetics of CCX025 over a range of dose levels. In preclinical studies, the...

2008-10-15 09:00:08

MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire/ -- ChemoCentryx, Inc., announced today that it has initiated a Phase I clinical trial of CCX025, the company's fourth investigational new drug and second orally administered compound that inhibits the chemokine receptor known as CCR9. Structurally distinct from Traficet-EN(TM) (CCX282-B; ChemoCentryx's CCR9 antagonist currently in a Phase II/III clinical trial for Crohn's disease), CCX025 strengthens ChemoCentryx's position in the CCR9 arena and...

2008-09-16 15:00:38

U.S. medical scientists say they have created a synthetic form of a protein that is involved in certain types of cancer and immune system diseases. Researchers at the Medical College of Wisconsin-Milwaukee said they have applied for a patent on the protein, CXCL12, which is known as a chemokine. Chemokines are proteins that regulate the movement of cells into tissues and recruit infection-fighting white blood cells to infected and injured sites, the scientists said. The study was led by...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related